oxybutynin has been researched along with Spinal Cord Injuries in 33 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to determine the effects of transdermal nitroglycerine on shoulder pain and on functional shoulder movement in patients with spinal cord injuries and shoulder tendinopathies." | 9.15 | Transdermal nitroglycerine treatment of shoulder tendinopathies in patients with spinal cord injuries. ( Alcanyis-Alberola, M; García-Massó, X; Giner-Pascual, M; Gonzalez, LM; Querol, F; Salinas-Huertas, S, 2011) |
| "This study aims to determine the effects of transdermal nitroglycerine on shoulder pain and on functional shoulder movement in patients with spinal cord injuries and shoulder tendinopathies." | 5.15 | Transdermal nitroglycerine treatment of shoulder tendinopathies in patients with spinal cord injuries. ( Alcanyis-Alberola, M; García-Massó, X; Giner-Pascual, M; Gonzalez, LM; Querol, F; Salinas-Huertas, S, 2011) |
| " The capsaicin 8% patch is a Food and Drug Administration-approved treatment of neuropathic pain in postherpetic neuralgia and has demonstrated significant efficacy in human immunodeficiency virus-autonomic neuropathy." | 3.81 | Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports. ( Trbovich, M; Yang, H, 2015) |
| "The effect of intravesical oxybutynin hydrochloride on detrusor behaviour was studied in 15 patients with urinary incontinence due to detrusor hyper-reflexia by ambulatory bladder monitoring." | 3.68 | Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. ( O'Flynn, KJ; Thomas, DG, 1993) |
| " Following a 7-day washout period, patients were evaluated via video-urodynamic study and then treatment was initiated at a dosage of 10 mg per day." | 2.71 | Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. ( Chancellor, MB; Erickson, JR; Horton, J; McDermott, C; O'Leary, M; Smith, CP, 2003) |
| " The side effect profile (dry mouth) was comparable between tolterodine, 2 mg twice daily, and placebo, but differed significantly when comparing tolterodine SSD with oxybutynin SSD (P < 0." | 2.71 | Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. ( Bard, RJ; Casey, AR; Ethans, KD; Nance, PW; Schryvers, OI, 2004) |
| " 21/32 patients became totally continent with the dosage (A)." | 2.69 | Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. ( Dörsam, J; Gerner, HJ; Haferkamp, A; Staehler, G, 2000) |
| "Oxybutynin is a mainstay of treatment in pediatric populations despite significant side effects and highly variable bioavailability." | 1.72 | Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder. ( Campbell, JG; Koenig, JF; Malik, MF; McLaughlin, MJ; Randall, JH, 2022) |
| ", whereas 47 (45,2%) used a lower dosage and 28 (26." | 1.39 | The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study. ( De Nunzio, C; Del Popolo, G; Finazzi-Agrò, E; Finita Celso, M; Lombardi, G; Perugia, C; Topazio, L, 2013) |
| "Propiverine was better tolerated than oxybutynin, having fewer adverse drug reactions (9." | 1.35 | Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Domurath, B; Henne, T; Körner, I; Madersbacher, H; Mürtz, G; Niedeggen, A; Nounla, J; Pannek, J; Schulte-Baukloh, H; Schultz-Lampel, D; Strugala, G, 2009) |
| "Oxybutynin-TDS was efficacious in spinal cord injury patients with neurogenic detrusor overactivity and was well tolerated at up to 3 times the standard dose." | 1.35 | Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. ( Foote, JE; Kennelly, MJ; Lemack, GE; Trop, CS, 2009) |
| "To evaluate type of neurogenic bladder and to observe changes of autonomous detrusor contraction (ADC) after the normalization of the compliance and capacity of the bladder in cauda equina injury." | 1.31 | Significance of low compliance bladder in cauda equina injury. ( Kim, HJ; Lee, IY; Park, CI; Shin, JC, 2002) |
| "Post oxybutynin the pressures were 83, 163, 95, 40, 30, and 68 (mean 79." | 1.29 | Intravesical oxybutynin in patients with posterior rhizotomies and sacral anterior root stimulators. ( Singh, G; Thomas, DG, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.09) | 18.7374 |
| 1990's | 8 (24.24) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Malik, MF | 1 |
| Randall, JH | 1 |
| Campbell, JG | 1 |
| McLaughlin, MJ | 1 |
| Koenig, JF | 1 |
| Ferreira, RS | 1 |
| D'Ancona, CAL | 1 |
| Oelke, M | 1 |
| Carneiro, MR | 1 |
| Finazzi-Agrò, E | 1 |
| Topazio, L | 1 |
| Perugia, C | 1 |
| Lombardi, G | 1 |
| Finita Celso, M | 1 |
| De Nunzio, C | 1 |
| Del Popolo, G | 2 |
| Hadiji, N | 1 |
| Previnaire, JG | 1 |
| Benbouzid, R | 1 |
| Robain, G | 1 |
| Leblond, C | 1 |
| Mieusset, R | 1 |
| Enjalbert, M | 1 |
| Soler, JM | 1 |
| Wada, N | 1 |
| Shimizu, T | 1 |
| Takai, S | 1 |
| Shimizu, N | 1 |
| Tyagi, P | 1 |
| Kakizaki, H | 1 |
| Yoshimura, N | 2 |
| Fujimura, M | 1 |
| Izumimoto, N | 1 |
| Kanie, S | 1 |
| Kobayashi, R | 1 |
| Yoshikawa, S | 1 |
| Momen, S | 1 |
| Hirakata, M | 1 |
| Komagata, T | 1 |
| Okanishi, S | 1 |
| Iwata, M | 1 |
| Hashimoto, T | 1 |
| Doi, T | 1 |
| Kawai, K | 1 |
| Nakayama, M | 1 |
| Távora, DG | 1 |
| Gama, RL | 1 |
| Silva, CE | 1 |
| Madersbacher, H | 1 |
| Mürtz, G | 1 |
| Alloussi, S | 1 |
| Domurath, B | 1 |
| Henne, T | 1 |
| Körner, I | 1 |
| Niedeggen, A | 1 |
| Nounla, J | 1 |
| Pannek, J | 2 |
| Schulte-Baukloh, H | 1 |
| Schultz-Lampel, D | 1 |
| Bock, P | 1 |
| Strugala, G | 1 |
| Kennelly, MJ | 1 |
| Lemack, GE | 1 |
| Foote, JE | 1 |
| Trop, CS | 1 |
| Wang, QW | 1 |
| Song, DK | 1 |
| Zhang, XP | 1 |
| Wu, YD | 1 |
| Zhang, RL | 1 |
| Wei, JX | 1 |
| Wen, JG | 1 |
| Shin, JC | 1 |
| Park, CI | 1 |
| Kim, HJ | 1 |
| Lee, IY | 1 |
| O'Leary, M | 1 |
| Erickson, JR | 1 |
| Smith, CP | 1 |
| McDermott, C | 1 |
| Horton, J | 1 |
| Chancellor, MB | 3 |
| Ethans, KD | 1 |
| Nance, PW | 1 |
| Bard, RJ | 1 |
| Casey, AR | 1 |
| Schryvers, OI | 1 |
| Gacci, M | 1 |
| Macchiarella, A | 1 |
| Celso, M | 1 |
| Vittori, G | 1 |
| Lapini, A | 1 |
| Serni, S | 1 |
| Sandner, P | 1 |
| Maggi, M | 1 |
| Carini, M | 1 |
| George, J | 1 |
| Tharion, G | 1 |
| Richar, J | 1 |
| Macaden, AS | 1 |
| Thomas, R | 1 |
| Bhattacharji, S | 1 |
| Singh, G | 2 |
| Thomas, DG | 2 |
| Rivas, DA | 2 |
| Huang, B | 1 |
| Salzman, SK | 1 |
| Szollar, SM | 1 |
| Lee, SM | 1 |
| Shenot, PJ | 1 |
| Watanabe, T | 1 |
| Kumon, H | 1 |
| Figueroa, TE | 1 |
| Kim, YH | 1 |
| Bird, ET | 1 |
| Priebe, M | 1 |
| Boone, TB | 1 |
| Vaidyananthan, S | 1 |
| Soni, BM | 2 |
| Brown, E | 1 |
| Sett, P | 2 |
| Krishnan, KR | 1 |
| Bingley, J | 1 |
| Markey, S | 1 |
| O'Flynn, KJ | 1 |
| Singas, E | 1 |
| Grimm, DR | 1 |
| Almenoff, PL | 1 |
| Lesser, M | 1 |
| Sommerfeld, HJ | 1 |
| Bötel, U | 1 |
| Senge, T | 1 |
| Haferkamp, A | 1 |
| Staehler, G | 1 |
| Gerner, HJ | 1 |
| Dörsam, J | 1 |
| Lose, G | 1 |
| Nørgaard, JP | 1 |
| Vaidyanathan, S | 1 |
| Hughes, PL | 1 |
| Parsons, KF | 1 |
| Bodner, DR | 1 |
| Lindan, R | 1 |
| Leffler, E | 1 |
| Resnick, MI | 1 |
| Fanciullacci, F | 1 |
| Zanollo, A | 1 |
| Sandri, S | 1 |
| Catanzaro, F | 1 |
| Tempkin, A | 1 |
| Sullivan, G | 1 |
| Paldi, J | 1 |
| Perkash, I | 1 |
| Pires, LR | 1 |
| Lopes, CDF | 1 |
| Salvador, D | 1 |
| Rocha, DN | 1 |
| Pêgo, AP | 1 |
| Trbovich, M | 1 |
| Yang, H | 1 |
| Giner-Pascual, M | 1 |
| Alcanyis-Alberola, M | 1 |
| Querol, F | 1 |
| Salinas-Huertas, S | 1 |
| García-Massó, X | 1 |
| Gonzalez, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury[NCT00224029] | Phase 4 | 24 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04)[NCT01050114] | Phase 3 | 36 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action[NCT01682603] | Phase 2 | 34 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline in number of daily catheterizations without leaking per day as recorded in a 3-day urinary diary. (NCT00224029)
Timeframe: 8 weeks
| Intervention | Number of Dry Catheterizations per Day (Mean) | |
|---|---|---|
| Baseline at Week 0 | Change from baseline at Week 8 | |
| Oxybutynin Transdermal System | 2.4 | 1.5 |
(NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | participants (Number) | |
|---|---|---|
| Post-Autonomic dysreflexia | Post-Non Autonomic dysreflexia | |
| Pre-Autonomic Dysreflexia | 5 | 6 |
| Pre-Non Autonomic Dysreflexia | 1 | 22 |
"Bladder compliance is the result of a mathematical calculation of the volume required for a unit rise of pressure measured during a cystometric filling.~Bladder compliance is calculated by dividing the volume change by the change in bladder pressure (mL/cmH2O).~Efficacy:~Net change of the bladder compliance from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL/cmH2O (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 30.6 | 29.0 |
"Efficacy:~Net change of the cystometric bladder capacity (CBC) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 305.9 | 437.6 |
"Efficacy:~Net change of the detrusor pressure (Pdet) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | cmH2O (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 36.1 | 12.9 |
"Efficacy:~Net change of the Incontinence Impact Questionnaire (IIQ-7) from baseline and 12 months.~The IIQ-7 is a 7-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~Total IIQ-7 score ranges = 0 to 21 The total IIQ-7 score can therefore range from 0 to 21 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 11.9 | 5.57 |
"Efficacy:~Net change of the maximum flow rate (Qmax) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL/s (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 4.56 | 3.54 |
"Efficacy:~Net change of the postvoid residual volume (PVR) from baseline and 12 months~Results:~Botulinum toxin A injection have increased postvoid residual urine volume in patients treated for bladder dysfunction.~Treat only patients who are willing and able to initiate catheterization post-treatment, if required, for urinary retention.~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 226.3 | 378.5 |
"Efficacy:~Net change of the quality of life index (QoL-I) from baseline and 12 months. The QoL-I on a 7-point scale ranging from 0 Delighted to 6 Terrible. The QoL-I ranges 0 to 6~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 4.00 | 2.21 |
"Efficacy:~Net change of the UrinaryDdistress Inventory (UDI-6) from baseline and 12 months.~The UDI-6 is a 6-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~The total UDI-6 score can therefore range from 0 to 18 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 10.4 | 7.43 |
"Efficacy:~Net change of the void volume from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline | 12 months | |
| Botulinum Toxin A | 79.6 | 59.2 |
1 review available for oxybutynin and Spinal Cord Injuries
| Article | Year |
|---|---|
Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
Topics: Administration, Intravesical; Child; Cholinergic Antagonists; Humans; Mandelic Acids; Spinal Cord In | 2001 |
12 trials available for oxybutynin and Spinal Cord Injuries
| Article | Year |
|---|---|
Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Topics: Acetylcholine Release Inhibitors; Administration, Oral; Adult; Botulinum Toxins, Type A; Female; Fol | 2018 |
Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
Topics: Adult; Aged; Autonomic Dysreflexia; Delayed-Action Preparations; Dose-Response Relationship, Drug; F | 2003 |
Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Topics: Adult; Benzhydryl Compounds; Cresols; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; | 2004 |
Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dysfunc | 2007 |
The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury.
Topics: Administration, Intravesical; Adolescent; Adult; Capsaicin; Drug Therapy, Combination; Female; Human | 2007 |
Intravesical oxybutynin for spinal cord injury patients.
Topics: Adult; Aged; Cholinergic Antagonists; Humans; Injections; Mandelic Acids; Middle Aged; Spinal Cord I | 1996 |
Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction.
Topics: Adult; Female; Humans; Injections; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Quality of | 1998 |
Inhibition of airway hyperreactivity by oxybutynin chloride in subjects with cervical spinal cord injury.
Topics: Adult; Aerosols; Bronchial Hyperreactivity; Bronchodilator Agents; Cholinergic Antagonists; Histamin | 1999 |
Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Topics: Administration, Intravesical; Administration, Oral; Adolescent; Cholinergic Antagonists; Female; Hum | 2000 |
Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Cholinergic Antagonists; C | 2000 |
The effect of verapamil on the treatment of detrusor hyperreflexia in the spinal cord injured population.
Topics: Adult; Calcium Channel Blockers; Female; Humans; Male; Mandelic Acids; Middle Aged; Reflex; Spinal C | 1989 |
Transdermal nitroglycerine treatment of shoulder tendinopathies in patients with spinal cord injuries.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Nitroglycerin; Placebo Effect; Should | 2011 |
20 other studies available for oxybutynin and Spinal Cord Injuries
| Article | Year |
|---|---|
Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder.
Topics: Child; Female; Humans; Male; Mandelic Acids; Retrospective Studies; Spinal Cord Injuries; Urinary Bl | 2022 |
The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study.
Topics: Adult; Botulinum Toxins, Type A; Chi-Square Distribution; Dose-Response Relationship, Drug; Female; | 2013 |
Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients?
Topics: Adult; Benzilates; Female; Humans; Male; Mandelic Acids; Nortropanes; Retrospective Studies; Spinal | 2014 |
Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Therapy, Co | 2017 |
Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex.
Topics: Afferent Pathways; Analgesics, Opioid; Animals; Electric Stimulation; Guinea Pigs; Male; Mandelic Ac | 2017 |
Sonographic evaluation of gallbladder contractility in patients with spinal cord injury.
Topics: Adult; Biliary Dyskinesia; Case-Control Studies; Dietary Fats; Female; Gallbladder Emptying; Humans; | 2008 |
Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Epidemiologic Methods; Female; Humans; Infant; Male | 2009 |
Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Topics: Administration, Cutaneous; Adult; Drug Dosage Calculations; Female; Humans; Male; Mandelic Acids; Mi | 2009 |
Urodynamic parameters development and complications of clean intermittent self-catheterization in Chinese schoolchildren with neurogenic underactive bladder.
Topics: Child; Child, Preschool; China; Female; Fever; Follow-Up Studies; Humans; Male; Mandelic Acids; Spin | 2011 |
Significance of low compliance bladder in cauda equina injury.
Topics: Administration, Intravesical; Administration, Oral; Adult; Benzilates; Cauda Equina; Compliance; Fem | 2002 |
Intravesical oxybutynin in patients with posterior rhizotomies and sacral anterior root stimulators.
Topics: Administration, Intravesical; Adult; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholytics; | 1995 |
Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents.
Topics: Adrenergic alpha-Antagonists; Animals; Autonomic Nervous System Diseases; Calcium Channel Blockers; | 1995 |
In-vivo whole bladder response to anticholinergic and musculotropic agents in spinal cord injured rats.
Topics: Animals; Cholinergic Antagonists; Dose-Response Relationship, Drug; Flavoxate; Male; Mandelic Acids; | 1997 |
The role of oxybutynin in spinal cord injured patients with indwelling catheters.
Topics: Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Cholinergic Antagonists; Humans; Male; Mandel | 1997 |
Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia.
Topics: Administration, Intravesical; Humans; Mandelic Acids; Multiple Sclerosis; Parasympatholytics; Reflex | 1993 |
Vesicoureteral reflux and bladder management in spinal cord injury patients.
Topics: Accidental Falls; Administration, Oral; Aged; Combined Modality Therapy; Follow-Up Studies; Humans; | 2002 |
The neuropathic bladder in children with spinal cord injury.
Topics: Catheterization; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Kidney Diseases; Male; | 1988 |
Radioisotope renography in spinal cord injury.
Topics: Adult; Humans; Male; Mandelic Acids; Middle Aged; Radioisotope Renography; Retrospective Studies; Sp | 1985 |
Ibuprofen-loaded fibrous patches-taming inhibition at the spinal cord injury site.
Topics: Animals; Cells, Cultured; Dioxanes; Drug Carriers; Drug Delivery Systems; Ibuprofen; Mice; Microtech | 2017 |
Capsaicin 8% Patch for Central and Peripheral Neuropathic Pain of Persons with Incomplete Spinal Cord Injury: Two Case Reports.
Topics: Adult; Aged; Capsaicin; Humans; Hyperalgesia; Male; Neuralgia; Pain Measurement; Sensory System Agen | 2015 |